Neupulse Secures £3 Million to Advance Tourette Syndrome Wearable Device Toward 2026 Launch
核心洞察
Neupulse (搜索) raised £3 million in funding led by Eos Advisory (搜索) and Midlands Engine Investment Fund II (搜索) to accelerate development of its non-drug wristband device for Tourette Syndrome (搜索) management.
The neurotherapeutics company plans to launch its wearable neuromodulation technology commercially in mid-2026, addressing critical gaps in current treatment options for the condition.
Tourette Syndrome (搜索) affects up to 2% of children worldwide, with current treatments limited to medication and behavioral therapy, neither considered ideal solutions by investors.
Neupulse (搜索), a UK-based neurotherapeutics company, has successfully raised £3 million in new funding to accelerate the development and commercialization of its innovative wristband device designed to manage Tourette Syndrome (搜索) symptoms. The funding round was led by Eos Advisory (搜索) and the Midlands Engine Investment Fund II (搜索), through appointed fund manager Mercia Ventures (搜索), with participation from existing and new investors.
The investment comes at a particularly challenging time for venture funding, underscoring strong investor confidence in Neupulse (搜索)'s neurotherapeutic approach. The company plans to use the capital to scale sales operations, advance regulatory progress, and support early commercialization efforts as it moves toward a commercial launch targeted for mid-2026.
Addressing Unmet Medical Need
Neupulse (搜索)'s wearable device represents a novel approach to treating Tourette Syndrome (搜索), a neurological condition that affects up to 2% of children worldwide according to Sandy Reid, Fund Principal at Mercia Ventures (搜索). Currently, treatment options are limited to medication and behavioral therapy, which Reid describes as less than ideal solutions.
"Tourette Syndrome (搜索) is believed to affect up to two per cent of all children worldwide but currently the only treatments are medication and behavioural therapy, neither of which are ideal solutions," Reid stated. "Neupulse (搜索)'s device offers a genuine alternative that could transform lives."
The company's technology combines scientific rigor with a focus on real-world impact, designed to address critical gaps in current treatment options through non-invasive neuromodulation delivered via a wearable wristband device.
Development Timeline and Previous Funding
This latest funding builds on Neupulse (搜索)'s previous £500,000 investment from the Midlands Engine Investment Fund II (搜索) in 2024, which supported the finalization of development for the non-drug treatment and clinical trials. The company, founded in 2021 as a spin-out from the University of Nottingham, has been developing the technology based on research from Professor Stephen Jackson, Professor Georgina Jackson, and Dr Barbara Morera.
Paul Cable, CEO of Neupulse (搜索), emphasized the significance of addressing unmet medical needs: "This investment underlines the unmet need in providing people with conditions like Tourette Syndrome (搜索) a solution to manage their condition, and as a company, we are driven to improve the lives of individuals with these conditions."
Commercial Strategy and Market Positioning
The funding enables Neupulse (搜索) to transition decisively from development toward commercial launch while continuing to build the evidence base required by clinicians, regulators, and healthcare systems. Ian Rhodes, Chair of the board at Neupulse, highlighted the broader economic implications: "This is a great example of advanced biomedical research from a leading UK university creating an initial UK market launch during 2026. This will increasingly benefit the UK economy as the technology scales out globally."
Andrew McNeill, Investor Director at Eos, expressed enthusiasm for supporting the company's commercialization phase: "We are delighted to support the next chapter of Neupulse (搜索) as they move towards commercialisation. This is exactly the kind of company and science we like to back. Passionate founders and technology with the potential to positively impact the lives of people across the globe."
Investor Confidence and Market Context
The successful funding round demonstrates strong investor confidence despite constrained venture capital markets. David Tindall, Senior Investment Manager at the British Business Bank (搜索), noted the company's impressive growth trajectory: "Neupulse (搜索)'s growth over the past year, following investment from the Midlands Engine Investment Fund II (搜索), has been impressive. By addressing a clear gap in the market and delivering a much-needed solution for those affected, the business exemplifies the Fund's commitment to backing ambitious, high-growth companies."
The Midlands Engine Investment Fund II (搜索), worth £400 million, provides debt finance from £25,000 to £2 million and equity investment up to £5 million to support small and medium-sized businesses across the Midlands region. The fund aims to drive sustainable economic growth by supporting innovation and creating opportunities for new and growing businesses.
Neupulse (搜索)'s continued momentum reflects growing demand for effective, clinically grounded neurotherapeutic solutions and positions the company for its next phase of growth as it prepares for market entry in the neurological device sector.